# AstraZeneca’s Brilinta approved in the US to reduce the risk of stroke

- Link: https://www.directorstalkinterviews.com/astrazenecas-brilinta-approved-in-the-us-to-reduce-the-risk-of-stroke/412935481
- Published: 2020-11-06T08:11:37+00:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
_Brilinta _has been approved in the US to reduce the risk of stroke, a leading cause
of disability and death worldwide, in patients with acute ischemic stroke or high-
risk transient ischaemic attack.

The approval by the US Food and Drug Administration (FDA) was based on positive 
results from the THALES Phase III trial that showed aspirin plus _Brilinta_ 90mg
significantly reduced the rate of the composite of stroke and death compared to 
aspirin alone in patients with acute ischaemic stroke or TIA.^(1) The decision follows
the Priority Review designation granted by the FDA in July 2020.

> **Dr. Clay Johnston, lead investigator for the THALES Phase III trial and Dean
> of the Dell Medical School at The University of Texas in Austin, US, said:** “
> One in four patients who have had a stroke will experience a second one, with 
> the risk particularly high within the first 30 days. The approval of _Brilinta_
> in combination with aspirin is an important advancement to reduce the risk of 
> recurrent stroke and much-awaited good news for physicians and patients.”

> **Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said**: “In
> the US, someone has a stroke every 40 seconds and the impact on a person’s life
> can be truly devastating. _Brilinta_ is a well-established medicine across patients
> with coronary artery disease and with today’s approval, we can now expand its 
> potential to patients with an acute ischaemic stroke or transient ischemic attack.”

The THALES trial demonstrated that _Brilinta_ 90mg used twice daily and taken with
daily aspirin for 30 days, reduced the rate of the primary composite endpoint of
stroke and death by 17% (absolute risk reduction = 1.1%; hazard ratio 0.83; 95% 
confidence interval 0.71-0.96, p=0.015), compared to aspirin alone in patients with
an acute ischemic stroke or TIA.^(1) This was a statistically significant and clinically
meaningful reduction. The primary composite endpoint was driven by a reduction in
stroke.

The risk for severe bleeding events was 0.5% in patients receiving aspirin plus 
_Brilinta_ and 0.1% for aspirin alone. The results were in line with the known safety
profile of _Brilinta_.^(1) Full data from the THALES Phase III trial can be found
in The New England Journal of Medicine.

Regulatory submissions to expand the approved indication are also under regulatory
review in China and in the EU where the medicine’s name is _Brilique_.

_Brilinta_ is approved in more than 110 countries for the prevention of atherothrombotic
events in adult patients with acute coronary syndrome (ACS) and in more than 70 
countries for the secondary prevention of cardiovascular events among patients who
are at high-risk and have experienced a heart attack. In May 2020, the US FDA approved
a new indication for _Brilinta_ to include the reduction of the risk of a first 
heart attack or stroke in high-risk patients with coronary artery disease.

**Stroke**

An ischaemic stroke is caused by a blockage cutting off the blood supply to a region
of the brain. A transient ischaemic attack, is a temporary blockage of the blood
supply to a region of the brain, resulting in symptoms only lasting for a short 
amount of time. Stroke is a leading cause of disability and death worldwide.^(2)
In the US, someone has a stroke every 40 seconds, and every four minutes, someone
dies of stroke.^(3) About one in four strokes are recurrent, with the risk particularly
high within 30 days after the initial event and even higher when looking at time
periods closer to the initial event.^(4,5)

**THALES**

THALES is an AstraZeneca-sponsored, randomised, placebo-controlled, double-blinded,
international, multicentre, event-driven Phase III trial involving more than 11,000
patients from 28 countries. It tested the hypothesis whether aspirin plus _Brilinta_
is superior to aspirin alone in preventing the composite of stroke and death in 
patients with non-cardioembolic acute ischaemic stroke or high-risk TIA. Patients
were randomised within 24 hours of onset of acute ischaemic stroke or high-risk 
TIA symptoms and treated for 30 days. Study treatments were _Brilinta_ 180mg loading
dose on day 1, followed by 90mg twice daily on days 2-30, or matching placebo. All
patients received open-label aspirin 300-325mg on day 1, followed by 75-100mg once
daily on days 2-30. The primary efficacy outcome was the time to the composite endpoint
of stroke and death at 30 days. The primary safety outcome is time to first severe
bleeding event according to the Global Utilization of Streptokinase and Tissue Plasminogen
Activator for Occluded Coronary Arteries (GUSTO) definition, which includes fatal
bleedings, intracranial haemorrhage; and bleeding causing hemodynamic compromise
requiring intervention.

**Brilinta**

_Brilinta_ (ticagrelor) is an oral, reversible, direct-acting P2Y_(12) receptor 
antagonist that works by inhibiting platelet activation. _Brilinta_, together with
aspirin, has been shown to significantly reduce the risk of major adverse cardiovascular(
CV) events (heart attack, stroke or CV death), in patients with ACS or a history
of heart attack. In the US, _Brilinta_ is also indicated for the reduction of the
risk of a first heart attack or stroke in high-risk patients with coronary artery
disease.

Share on:
